Aligos Therapeutics, Inc. (ALGS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$1.89M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$26.93M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$28.36M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$18.57M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$1.89M | (m) | $0.00 | (m) | (m) | -$24.95M* | (m) | $24.05M | (m) | $2.81M |
| 2026-03-31 | Reported | (m) | -$26.93M | (m) | $2.83M | (m) | (m) | -$23.13M | (m) | $23.35M | (m) | $317.00K |
| 2025-09-30 | Reported | (m) | -$28.36M | (m) | $741.00K | (m) | (m) | -$24.34M* | (m) | $23.94M | (m) | $56.00K |
| 2025-06-30 | Reported | (m) | -$18.57M | (m) | $965.00K | (m) | (m) | -$15.50M* | (m) | $13.98M | (m) | $185.00K |
| 2025-03-31 | Reported | (m) | -$19.24M | (m) | $311.00K | (m) | (m) | -$20.91M | (m) | $14.50M | (m) | $43.00K |
| 2024-09-30 | Reported | (m) | -$20.13M | (m) | $1.25M | (m) | (m) | -$20.10M* | (m) | $16.77M | (m) | $91.00K |
| 2024-06-30 | Reported | (m) | -$26.41M | (m) | $1.06M | (m) | (m) | -$19.49M* | (m) | $21.10M | (m) | $189.00K |
| 2024-03-31 | Reported | (m) | -$22.05M | (m) | $694.00K | (m) | (m) | -$22.75M | (m) | $16.37M | (m) | $24.00K |
| 2023-09-30 | Reported | (m) | -$19.07M | (m) | $1.08M | (m) | (m) | -$20.34M* | (m) | $15.87M | (m) | $29.00K |
| 2023-06-30 | Reported | (m) | -$19.14M | (m) | $4.29M | (m) | (m) | -$13.62M* | (m) | $16.78M | (m) | $757.00K |
| 2023-03-31 | Reported | (m) | -$23.92M | (m) | $140.00K | (m) | $7.00K | -$22.39M | (m) | $18.14M | (m) | $39.00K |
| 2022-09-30 | Reported | (m) | -$18.95M | (m) | $0.00 | (m) | $3.00K* | -$17.14M* | (m) | $17.79M | (m) | -$43.00K |
| 2022-06-30 | Reported | (m) | -$20.39M | (m) | $0.00 | (m) | $334.00K* | -$25.04M* | (m) | $16.51M | (m) | $47.00K |
| 2022-03-31 | Reported | (m) | -$35.56M | (m) | (m) | (m) | $515.00K | -$20.43M | (m) | $31.68M | (m) | $53.00K |
| 2021-09-30 | Reported | (m) | -$33.07M | (m) | (m) | (m) | $97.00K* | -$25.37M* | (m) | $28.13M | (m) | $126.00K |
| 2021-06-30 | Reported | (m) | -$29.57M | (m) | (m) | (m) | $152.00K* | -$23.02M* | (m) | $24.55M | (m) | $28.00K |
| 2021-03-31 | Reported | (m) | -$27.74M | (m) | (m) | (m) | $307.00K | -$29.80M | (m) | $22.87M | (m) | $45.00K |
| 2020-09-30 | Reported | (m) | -$21.56M | (m) | (m) | (m) | $344.00K* | -$16.57M* | (m) | $17.33M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$21.27M | (m) | (m) | (m) | $569.00K* | -$17.69M* | (m) | $17.18M | (m) | -$59.00K |
| 2020-03-31 | Reported | (m) | -$20.72M | (m) | (m) | (m) | $1.09M | -$20.32M | (m) | $17.30M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$14.50M | (m) | (m) | (m) | (m) | (m) | (m) | $11.73M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$87.98M | (m) | $2.19M | (m) | (m) | -$82.50M | (m) | $69.45M | (m) | $314.00K |
| 2024-12-31 | Reported | (m) | -$89.15M | (m) | $3.61M | (m) | $130.00K | -$80.74M | (m) | $70.27M | (m) | $331.00K |
| 2023-12-31 | Reported | (m) | -$88.13M | (m) | $6.19M | (m) | $19.00K | -$79.00M | (m) | $73.04M | (m) | $795.00K |
| 2022-12-31 | Reported | (m) | -$97.58M | (m) | $0.00 | (m) | $943.00K | -$79.39M | (m) | $85.08M | (m) | $106.00K |
| 2021-12-31 | Reported | (m) | -$128.32M | (m) | $0.00 | (m) | $892.00K | -$115.66M | (m) | $104.15M | (m) | $143.00K |
| 2020-12-31 | Reported | (m) | -$97.83M | (m) | $0.00 | (m) | $2.06M | -$74.26M | (m) | $79.89M | (m) | $161.00K |
| 2019-12-31 | Reported | (m) | -$54.04M | (m) | (m) | (m) | $2.79M | -$46.77M | (m) | $44.04M | (m) | $85.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |